Fujirebio said Health Canada cleared two neurological blood-based diagnostics for the Canadian market, both using its Lumipulse G platform. The approvals include a Class II Medical Device license for Lumipulse G NfL, measuring neurofilament light chain as a quantitative neuroaxonal injury biomarker, with stated potential relevance to MS. Health Canada also licensed Lumipulse G pTau 217, a plasma assay targeting Alzheimer’s-linked phosphorylated tau 217 to help differentiate neurodegeneration causes. The company said both tests received CE marking earlier in 2026, with NfL clearance in March and pTau 217 in May. The move broadens payer-ready biomarker options for clinicians using fully automated immunoassay workflows and reinforces the migration of neurological diagnostics into standardized blood tests.